Iconic cases, such as BCR–ABL1 found in chronic myeloid leukemia (CML) [6, 7] and TMPRSS2–ERG in prostate cancer [8, 9], have become effective therapeutic targets and critical diagnostic and prognostic markers [10, 11]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.